Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom Neft launched a new primary refining complex at the Omsk Refinery

9/22/23 SIBN

Polymetal to relocate Pacific MMC from Sovgavan to Kazakhstan

9/22/23 POLY

Fix Price launched delivery of goods via Yandex services

9/22/23 FIXP

Gazprombank and Mechel decided to reach an amicable agreement

9/22/23 MTLR

RuStore plans to increase its monthly audience to 25 mln by the end of the year

9/22/23 VKCO

Tatneft shareholders failed to approve dividends

9/22/23 TATN

Orders from Avito will be able to be received or sent via Yandex Market's POZs

9/22/23 YNDX

Lukoil stated the risk for its plant in Bulgaria

9/22/23 LKOH

Cisco buys Splunk

9/21/23 SPLK

Fesco plans to introduce unmanned ship management systems

9/21/23 FESH